Depo-provera Ci

  • Contraception

Depo-provera Ci Generic Name & Formulations

General Description

Medroxyprogesterone acetate 150mg/mL; IM inj.

Pharmacological Class


How Supplied

Vials—1, 25; Prefilled syringe (1mL)—1 (w. needles); SubQ (prefilled syringe)—1 (w. needle)


Depo-provera Ci Indications


Injectable contraception.

Limitations of Use

Not recommended as a long-term (eg, >2yrs) birth control method unless other options are considered inadequate.

Depo-provera Ci Dosage and Administration


Give by deep IM inj in the gluteal or deltoid muscle; rotate inj sites. 150mg every 3 months (13 weeks). Give 1st dose within 5 days of onset of normal menses (see full labeling for postpartum).


Pre-menarche: not applicable.

Depo-provera Ci Contraindications


Active thrombophlebitis. Thromboembolic disorders. Cerebrovascular disease. Breast carcinoma. Significant liver disease. Undiagnosed vaginal bleeding. Pregnancy.

Depo-provera Ci Boxed Warnings

Boxed Warning

Loss of bone mineral density.

Depo-provera Ci Warnings/Precautions


May lose significant bone mineral density (BMD). Evaluate BMD with long-term use or in adolescents. Risk for osteoporosis (eg, metabolic bone disease, anorexia, family history). Previous or family history of breast cancer (monitor closely). Ectopic pregnancy. History of depression; monitor for mood changes. Diabetes. Monitor conditions aggravated by fluid retention. Do pretreatment physical exam. Discontinue if jaundice or elevated transaminases, visual disturbances, migraine, or thrombotic disorders occur. Nursing mothers.

Depo-provera Ci Pharmacokinetics

See Literature

Depo-provera Ci Interactions


May be antagonized by moderate or strong CYP3A4 inducers (eg, bosentan, efavirenz, etravirine, modafinil, rifampin, carbamazepine, phenytoin, phenobarbital, mitotane, St. John's wort, others); avoid. May reduce bone mass with anticonvulsants, corticosteroids; avoid alcohol, tobacco. May be affected by protease inhibitors, NNRTIs. May affect results of lab tests (eg, coagulation factors, lipids, glucose tolerance, and binding proteins); see full labeling.

Depo-provera Ci Adverse Reactions

Adverse Reactions

Dysfunctional uterine bleeding, headache, increased weight, amenorrhea, inj site reactions, vaginitis, abdominal pain, UTIs, acne; decreased BMD, anaphylaxis.

Depo-provera Ci Clinical Trials

See Literature

Depo-provera Ci Note

Not Applicable

Depo-provera Ci Patient Counseling

See Literature